Objective: Analysis of safety and efficacy of recombinant activated factor VII (rFVIIa) used as the last resort for refractory bleeding after cardiac surgery.
B leeding requiring mediastinal exploration after cardiac surgery occurs in 3-5% of patients (1, 2) . Bleeding refractory to conventional hemostatic therapy is caused in part by disturbance of the hemostatic system due to preoperative antiplatelet therapy, consumption of co-agulation factors, hypothermia, hyperfibrinolysis, and platelet disorders (3) .
In this setting, various case reports (4 -6) have described the utility of recombinant activated factor VII (rFVIIa) in combination with conventional hemostatic therapy. The number of published patients is inadequate to establish safety of rFVIIa. These case reports do not assess the incremental efficacy of rFVIIa over the accompanying conventional hemostatic therapy.
We report a retrospective analysis of the use of rFVIIa in 24 consecutive patients who had refractory bleeding after cardiac surgery. They also received conventional hemostatic therapy including surgical reintervention. Because the safety of rFVIIa in this setting is not established, it was administered as a last resort, a median of 14 hrs after the index surgery. The aim of this study was to determine the safety of rFVIIa and its efficacy in reducing blood loss and transfusion requirements. To assess the incremental efficacy of rFVIIa over the accompanying conventional hemostatic therapy, we compared the rFVIIa group with a historical control group of patients who received only conventional hemostatic therapy.
PATIENTS AND METHODS
After approval by the local ethics committee, demographic, clinical, blood loss, transfusion, and coagulation data were collected retrospectively from the patients' charts. Between June 2000 and March 2003, approximately 4,100 cardiac surgeries were performed at our institution. Of these, 26 patients were treated with rFVIIa (Novoseven, No-voNordisk, Bagsvaerd, Denmark), as the last resort. No patient died because of bleeding without receiving rFVIIa. Two patients from this rFVIIa group were excluded from analysis because their data were incomplete due to death within the subsequent 24-hr observation period. These two patients died of refractory cardiogenic shock and septic multipleorgan failure that were not considered to be due to transfusion or rFVIIa. Two of the remaining 24 patients have been reported on previously (6, 7) .
Conventional hemostatic therapy included the administration of fresh frozen plasma, platelets, fibrinogen, prothrombin complex, factor XIII, and antithrombin and aimed at normalizing plasmatic coagulation, platelet count, and function. We also administered aprotinin and desmopressin (8 -11) . Aprotinin therapy was initiated by a bolus of 500,000 kallikrein inhibiting units (KIU) followed by a continuous infusion of 100,000 KIU/hr. In year 2002 this was replaced by a bolus of 2 million KIU followed by an infusion of 500,000 KIU/hr (11) . The dose of desmopressin was 0.3 g/kg every 12 hrs for a maximum of 2 days. In case of refractory bleeding despite an almost normalized coagulation profile, mediastinal exploration was considered if blood loss exceeded 1000 mL within 6 hrs after the index surgery. Fibrin glue was not used.
We administered rFVIIa if despite adequate conventional hemostatic therapy, excessive bleeding continued beyond a median of 14 hrs (interquartile range, 11 and 24 hrs) after the index surgery. Conventional hemostatic therapy was also continued. Data from time intervals of the end of index surgery to administration of the first dose of rFVIIa (observation period 1) and the subsequent 24 hrs (observation period 2) are presented.
The dose of rFVIIa was 60 -80 g/kg, chosen empirically on the basis of published reports. Second and third doses of rFVIIa were administered 4 -8 hrs later if the first dose did not lead to a reduction in blood loss to Ͻ100 mL/hr and a reduction in transfusion requirements (responder). If blood loss continued to be Ͼ100 mL/hr or mediastinal exploration for persistent bleeding was performed, treatment with rFVIIa was considered unsuccessful (nonresponder).
After administration of rFVIIa, we monitored creatine kinase and its myocardial subtype twice daily and blood lactate every 2 hrs. The screening for thromboembolic events was done by physical examination of the entire body. If a thromboembolic complication was suspected, various laboratory and other tests such as echocardiography and computed tomography scanning were performed. In patients who died, autopsy was performed if permitted.
To determine the incremental efficacy of rFVIIa over the accompanying conventional hemostatic therapy, we studied a historical matched pair control group of patients who received only conventional hemostatic therapy between the years 1998 and 2002. Data for the control group were collected for 14 hrs after index surgery (observation period 1) and the following 24 hrs (observation period 2).
The following criteria were used to select matching patients for inclusion in the control group: a) blood loss during the first 14 hrs Ͼ1000 mL; b) single procedure (single valve replacement or coronary artery bypass graft) vs. combined procedure (e.g., coronary artery bypass graft and valve replacement, coronary artery bypass graft and aneurysmectomy); c) recombinant hirudin for anticoagulation during cardiopulmonary bypass (12) .
Additional factors that predispose patients to bleeding were analyzed in the second step. These confounders included endocarditisrelated sepsis (13) , liver failure with reduced clotting factors (14) , preoperative use of platelet inhibitors (15, 16) , number of prior cardiac surgeries (17) , implantation of a ventricular assist device (18) , and the need for emergency surgery (19) .
Statistical Methods. Because of the small sample size, nonparametric statistics (SPSS for Windows, version 11.0, SPSS, Chicago, IL) were used, and results are presented as median and interquartile range. For dichotomous observations, the McNemar test for paired groups and Fisher's exact test for independent groups were used. For continuous variables, we applied Wilcoxon's paired signed rank test. For intergroup analyses, we used the Mann-Whitney U test. A two-tailed p Ͻ .05 was considered significant.
RESULTS
The demographic and clinical characteristics of the patients in the two groups are presented in Tables 1 and 2 . Table 3 describes the distribution of risk factors for bleeding. Preoperative liver failure and sepsis due to endocarditis were more frequent in the rF-VIIa group, whereas prior cardiac surgery, emergency surgery, ventricular assist devices, Preoperative coagulopathy, preoperative use of platelet inhibitors, thrombocytopenia, or liver failure; AVR, aortic valve replacement; CABG, coronary artery bypass grafting; LVAD, left ventricular assist device (centrifugal pump); MVR, mitral valve replacement; HIT II, heparin-induced thrombocytopenia type II; MVRecon, mitral valve reconstruction; RVAD, right ventricular assist device (centrifugal pump). and preoperative platelet inhibitors were more frequent in the control group.
rFVIIa Group. The first dose of rFVIIa was a median of 60 g/kg. The second dose was administered to ten (42%) patients for a median cumulative dose of 116 g/kg. The third dose was administered to two (8%) patients for a median cumulative dose of 187 g/kg.
We found that in the period after the administration of rFVIIa, there was a significant reduction in blood loss ( Fig. 1 ) and transfusions (Fig. 2) . The reduction in blood loss and transfusions was significant even when all 26 patients, including the two excluded patients who received rFVIIa, were considered.
For 18 of 24 (75%) patients, after the administration of rFVIIa there was a reduction in blood loss to Ͻ100 mL/hr and a reduction in administration of blood products, prothrombin, factor XIII, and antithrombin ( Table 4 and Figs. 1 and 2). These 18 patients were considered responders. After the administration of rF-VIIa, the rates of mediastinal exploration and administration of fibrinogen and aprotinin were not significantly changed (Table 4 ). International normalized ratio and activated partial thromboplastin time were reduced, fibrinogen was increased, but antithrombin and platelets were not significantly altered (Table 5 ).
After treatment with rFVIIa, six (25%) patients (nonresponders) had blood loss Ͼ100 mL/hr and had mediastinal exploration for bleeding (Table 4 ). In two of these patients, a surgical source of bleeding was identified. Two patients had refrac- Preoperative coagulopathy, preoperative use of platelet inhibitors, thrombocytopenia, or liver failure; AVR, aortic valve replacement; CABG, coronary artery bypass grafting; LVAD, left ventricular assist device (centrifugal pump); MVR, mitral valve replacement; AAR, ascending aorta replacement; TVrecon, tricuspid valve reconstruction; HIT II, heparin-induced thrombocytopenia type II. tory diffuse bleeding aggravated by the use of a left ventricular assist device for refractory cardiogenic shock. The remaining two patients had sepsis due to acute endocarditis.
The reasons for death among the 24 patients in the rFVIIa group, more than 24 hrs after the administration of the first dose of rFVIIa, were refractory cardiogenic shock (n ϭ 6), septic shock with multiple-organ failure (n ϭ 1), and decompensated liver failure (n ϭ 1). Death occurred in the intensive care unit (ICU) between postoperative days 1 and 9. In four of these eight patients, excessive blood loss persisted after rFVIIa, necessitating mediastinal exploration. After discharge from ICU, none of the remaining 16 patients died in hospital.
In three of the eight patients who died, an autopsy was performed showing no occlusion of bypass grafts or native coronary arteries. The reasons for death of the five patients in whom no autopsy was performed was considered to be unrelated to the administration of rFVIIa. No clinical signs of thromboembolic complications were detected in any of our patients.
Control Group. In the control group, a significant reduction in blood loss, transfusions ( Figs. 1 and 2) , and antithrombin administration (Table 4 ) occurred from observation period 1 (0-14 hrs after index surgery) to observation period 2 (15-38 hrs after index surgery). The incidence of mediastinal exploration and the administered amounts of coagulation factors other than antithrombin were not significantly different between the two periods ( Table 4 ). The coagulation profiles at the ends of observation periods 1 and 2 were not significantly different except that at the end of observation period 2 (Table 5) , the platelet count was lower and fibrinogen was higher. Seven (29%) patients in the control group were considered nonresponders to conventional hemostatic therapy because they underwent mediastinal exploration for persistent bleeding (Table 4 ). In three of these patients, a surgical source of bleeding was identified. The remaining four patients had refractory diffuse bleeding aggravated by the use of left ventricular assist device for refractory cardiogenic shock (n ϭ 3) or septic shock due to acute endocarditis (n ϭ 1).
The reasons for death Ͼ38 hrs after the index surgery in the control group were refractory cardiogenic shock (n ϭ 3), septic multiple-organ failure (n ϭ 4), and decompensated liver failure (n ϭ 1). rFVIIa Vs. Control Groups. During observation period 2, the only significant difference in transfusions was the lesser use of platelets in the control group (Fig.  2) . Table 5 shows that the international normalized ratios of prothrombin time and fibrinogen were significantly lower in the rFVIIa group, whereas antithrombin and platelet counts were significantly higher in the rFVIIa group. Acute Physiology and Chronic Health Evaluation II score, mortality rate, 6-month survival, and duration of ICU and hospital stays were not significantly different between the groups (Tables 3 and 6 ).
DISCUSSION
The prior reports (4 -6) of the use of rFVIIa for refractory bleeding after cardiac surgery did not adequately establish its safety and did not attempt to establish its incremental efficacy over the accompanying conventional hemostatic therapy. We found last-resort treatment with rFVIIa to be safe. However, the rFVIIa group and the historical control group treated without rF-VIIa had similar reduction in blood loss and transfusion requirements during observation period 2. In-hospital and 6-month mortality rates were not different (p ϭ 1.0) between our two groups. Our study does not support the incremental efficacy of lastresort treatment with rFVIIa over the accompanying conventional hemostatic therapy.
The possible reasons for the lack of difference between the two groups include: 1) the rFVIIa group started with greater bleeding at the end of observation period 1, and this group tended to have greater blood loss, more transfusions, greater use of coagulation factors and aprotinin, greater international normalized ratio and activated partial thromboplastin time, and lower fibrinogen and platelet count 9 (Tables 4, 5); 2) the five-fold higher incidence of preoperative liver failure in the rFVIIa group (Table 3) might have influenced transfusion requirements (14) ; 3) treatment with rFVIIa was delayed because when we started using it, its safety with respect to thromboembolic complications was not established. In our 26 patients, the use of rFVIIa caused no thromboembolic complications as assessed by clinical examination, laboratory tests, color-coded Doppler sonography, transesophageal echocardiography, and autopsy. Now that more data on safety of rFVIIa in this setting have been reported, earlier treatment with rFVIIa may be considered. Early use of rFVIIa during prostatectomy was demonstrated to have a transfusion-sparing effect (20) . On the other hand, the last-resort approach was ineffective in a case series of massively transfused patients after surgery (21); 4) our first median dose of 60 g/kg of rFVIIa was lower than that in some other case reports from cardiac surgery (5, 22) . The use of a second dose in ten patients and a third dose in two patients suggests that the first dose may have been too low. On the other hand, Al-Douri et al. (4) achieved hemostasis in severely bleeding patients during (n ϭ 4) or after (n ϭ 1) cardiac surgery with a single dose of 30 g/kg rFVIIa, although it may be argued that three of five patients in Al-Douri's case series were treated during surgery and only two patients in ICU. Furthermore, the need for repeated doses of rFVIIa in our study may be explained by a higher incidence of severe comorbidities. A more recent analysis by Karkouti et al. (23) showed that refractory bleeding was significantly reduced with rFVIIa (mean dose between 37 Ϯ 9 and 62 Ϯ 13 g/kg) compared with a historic control group. The authors of this study stated that their results were confounded by time, which possibly explains the different results to our analysis.
CONCLUSIONS
We found that after the administration of rFVIIa in combination with conventional hemostatic therapy, there were no thromboembolic complications, and blood loss and transfusions were significantly reduced. However, when compared with a historical control group that received only conventional hemostatic therapy, blood loss, transfusions, and the need for mediastinal exploration were not significantly less in the period after the administration of rFVIIa. Our results support the safety of last-resort therapy with rFVIIa but not its incremental efficacy over conventional hemostatic therapy. The evaluation of the efficacy of rFVIIa for different causes of bleeding (e.g., hirudin anticoagulation, hyperfibrinolysis, or inadequate platelets) and optimal timing and dosing of rFVIIa requires a prospective, dose-escalating study that randomizes patients between conventional hemostatic therapy with rFVIIa vs. conventional hemostatic therapy. 
